Analysing the Surface of Suspension Growth Adapted Chinese Hamster Ovary Cells

Total Page:16

File Type:pdf, Size:1020Kb

Analysing the Surface of Suspension Growth Adapted Chinese Hamster Ovary Cells Adaptation to suspension growth: analysing the surface of suspension growth adapted Chinese hamster ovary cells by Christa G Walther submitted for the degree of Doctor of Philosophy Department of Chemical and Biological Engineering January 2013 Analysing the surface of suspension growth adapted CHO cells Statement of Originality: The work presented in this thesis is to the best of my knowledge and belief original, except as acknowledged in the text. I hereby declare that I have not submitted this material, either in whole or in part, for a degree at this or any other institution. January 2013 -2- Analysing the surface of suspension growth adapted CHO cells dedicated to my mum Rita Wolters * 1932 † 2009 Du fehlst. -3- Analysing the surface of suspension growth adapted CHO cells Acknowledgement I would like to thank Prof. David C. James and Dr. Mark Leonard for the opportunity to work on this project and learn about bio-pharmaceutical production in CHO cells. I am grateful for the feedback and input I got from Dr. Robin Heller-Harrison and Dr. Mark Melville, both previously at Wyeth (now Pfizer), during the first two years of the project. Also I would like to thank Pfizer for the financial support. Rob Whitfield, who has been using the same cell lines in his PhD project, was always helpful with tips on cell culture, cell splitting during times of holiday and organised the continuous flow of the proprietary media by sending lots of emails and handling the huge delivery boxes. For the supply with the media a big thank you goes as well to the media production department at Pfizer and to Steve Brennan for organising the shipments. I am really grateful for the help I got at the Sheffield Medical School from Sue Newton and Kay Hopkinson, who answered every question about flow cytometry I had and also found alternative instruments to measure on when need arose. At the Kroto Research Institute, Dr. Nicola Green introduced me to confocal microscopy, trained me patiently on the use of the confocal microscope and helped with all questions I had. I enjoyed working with the different nationalities and personalities in the group; to Olivia Mozley a big thank you for understanding my English when I myself wasn't too sure what I was trying to say and for discussing confocal experiment set-up. More thanks go to Dr. Paul Dobson, who undertook the effort to read a thesis draft, and to Dr. Henriette Jensen, Dr. Esther Karunakaran and Dr. Phil Jackson for their feedback on single chapters. I would also like to thank my sister, my father and my friends in Germany who, although they found the project rather unexciting, continued to be interested in my progress. Finally, I would like to thank my husband Thomas, who besides doing a lot of cooking over the last years to keep us alive (he is now a much better cook than I am), also tried hard to learn and understand major biological terms in order to perhaps become able to understand my project. He also made sure that typical German grammar mistakes have been kept to a minimum. I promise him to not be as short tempered next year as during the last months. -4- Analysing the surface of suspension growth adapted CHO cells Abstract Many bio-pharmaceutical production processes are based upon the use of mammalian cell lines, such as Chinese hamster ovary (CHO) cells, capable of proliferation as single cells in suspension in a synthetic environment. Routine use of CHO cells as production vehicles requires a lengthy “adaptation” process from the wild-type adherent clone to clones capable of proliferation in a suspension environment depleted of exogenous growth factors and cell-matrix contacts. Different approaches have been applied in this study to gain a better understanding of the changes on the cell surface occurring as a response to changes in their environment, comparing four cell lines (CCL61, AML, S cells and CHO-S) adapted to suspension or adherence growth condition. Biochemistry and mass spectrometry methods showed differences in surface protein composition for the cell lines. The comparison of the expression of cell-to-cell adhesion molecules revealed a highly variable bimodal distribution on S cells which was not seen on CCL61. Analysis of the expression level of integrins, the main interaction partner of serum components, indicated that integrin expression is not generally down-regulated on suspension-adapted CHO cells. The integrin conformation on the cell surface, analysed by confocal microscopy, revealed a specific conformation, especially with regard to integrin beta 1, characterised by an even, net-like distribution of integrin clusters over the surface of the cells. This specific integrin conformation, which has only been found on suspension-adapted cells, was underlined by a sub-cortical sheet of actin, forming a ball-like structure directly under the cell membrane; this actin conformation required re-organisation of the actin cytoskeleton from a typical fibrillar morphology in adherent cells. The actin content was higher in suspension cell lines compared to adherent cells, but actin up- regulation was also found in non-suspension adapted cells after they had been transferred into suspension.. Sphere-like integrin beta 1 clustering on CCL61 grown in suspension could be induced by treatment with cytochalasin D, followed by suspension culture without the drug, however, despite the change in integrin beta 1 conformation these cells could not grow in suspension. The data suggests that adaptation to suspension growth requires conservation of integrins, presumably with respect to their role as structural elements anchoring the plasma membrane to the sub-cortical actin sheath, but it also requires additional changes in the interplay between integrin beta 1 and actin, for example, changes in the regulation of the associated proteins for successful suspension adaptation of CHO cells. -5- Analysing the surface of suspension growth adapted CHO cells Table of Contents List of Tables ............................................................................................................................... 11 List of Figures ............................................................................................................................. 12 Abbreviations and Synonyms........................................................................................................15 1. Chapter Introduction ................................................................................................................................. 17 1.1 Basic background .............................................................................................................. 17 1.2 Objectives and Approaches used ....................................................................................... 19 1.3 Summary of the main results ............................................................................................ 20 2. Chapter Chinese hamster ovary cells as a production vehicle that requires suspension adaptation ........ 22 2.1 Chinese hamster ovary cells for bio-pharmaceutical production ...................................... 22 2.2 Cell surface changes as a reaction to a new environment ................................................. 24 3. Chapter Experimental techniques ............................................................................................................ 31 3.1 Cell lines ........................................................................................................................... 31 3.2 Cell culture conditions ...................................................................................................... 31 3.2.1 Suspension culture ..................................................................................................... 31 3.2.2 Adherent culture ........................................................................................................ 21 3.3 Cell preparation for flow cytometry ................................................................................. 32 3.4 Cell preparation for confocal microscopy ......................................................................... 32 3.5 Flow cytometry – instrumentation set-up ......................................................................... 33 3.6 Confocal microsopy - instrumentation set-up ................................................................... 33 3.7 Actin labelling ................................................................................................................... 33 3.7.1 Actin: flow cytometry staining .................................................................................. 33 3.7.2 Actin: confocal microscopy staining ......................................................................... 34 3.8 Integrin beta 1 labelling .................................................................................................... 34 3.8.1 Integrin beta 1: flow cytometry staining ................................................................... 34 3.8.2 Integrin beta 1: confocal microscopy staining .......................................................... 34 3.9 Integrin alpha 1 labelling .................................................................................................. 35 3.9.1 Integrin alpha 1: flow cytometry staining ................................................................. 35 -6- Analysing the surface of suspension growth adapted CHO cells 3.9.2 Integrin alpha 1: confocal microscopy staining .......................................................
Recommended publications
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • CD Markers Are Routinely Used for the Immunophenotyping of Cells
    ptglab.com 1 CD MARKER ANTIBODIES www.ptglab.com Introduction The cluster of differentiation (abbreviated as CD) is a protocol used for the identification and investigation of cell surface molecules. So-called CD markers are routinely used for the immunophenotyping of cells. Despite this use, they are not limited to roles in the immune system and perform a variety of roles in cell differentiation, adhesion, migration, blood clotting, gamete fertilization, amino acid transport and apoptosis, among many others. As such, Proteintech’s mini catalog featuring its antibodies targeting CD markers is applicable to a wide range of research disciplines. PRODUCT FOCUS PECAM1 Platelet endothelial cell adhesion of blood vessels – making up a large portion molecule-1 (PECAM1), also known as cluster of its intracellular junctions. PECAM-1 is also CD Number of differentiation 31 (CD31), is a member of present on the surface of hematopoietic the immunoglobulin gene superfamily of cell cells and immune cells including platelets, CD31 adhesion molecules. It is highly expressed monocytes, neutrophils, natural killer cells, on the surface of the endothelium – the thin megakaryocytes and some types of T-cell. Catalog Number layer of endothelial cells lining the interior 11256-1-AP Type Rabbit Polyclonal Applications ELISA, FC, IF, IHC, IP, WB 16 Publications Immunohistochemical of paraffin-embedded Figure 1: Immunofluorescence staining human hepatocirrhosis using PECAM1, CD31 of PECAM1 (11256-1-AP), Alexa 488 goat antibody (11265-1-AP) at a dilution of 1:50 anti-rabbit (green), and smooth muscle KD/KO Validated (40x objective). alpha-actin (red), courtesy of Nicola Smart. PECAM1: Customer Testimonial Nicola Smart, a cardiovascular researcher “As you can see [the immunostaining] is and a group leader at the University of extremely clean and specific [and] displays Oxford, has said of the PECAM1 antibody strong intercellular junction expression, (11265-1-AP) that it “worked beautifully as expected for a cell adhesion molecule.” on every occasion I’ve tried it.” Proteintech thanks Dr.
    [Show full text]
  • HCC and Cancer Mutated Genes Summarized in the Literature Gene Symbol Gene Name References*
    HCC and cancer mutated genes summarized in the literature Gene symbol Gene name References* A2M Alpha-2-macroglobulin (4) ABL1 c-abl oncogene 1, receptor tyrosine kinase (4,5,22) ACBD7 Acyl-Coenzyme A binding domain containing 7 (23) ACTL6A Actin-like 6A (4,5) ACTL6B Actin-like 6B (4) ACVR1B Activin A receptor, type IB (21,22) ACVR2A Activin A receptor, type IIA (4,21) ADAM10 ADAM metallopeptidase domain 10 (5) ADAMTS9 ADAM metallopeptidase with thrombospondin type 1 motif, 9 (4) ADCY2 Adenylate cyclase 2 (brain) (26) AJUBA Ajuba LIM protein (21) AKAP9 A kinase (PRKA) anchor protein (yotiao) 9 (4) Akt AKT serine/threonine kinase (28) AKT1 v-akt murine thymoma viral oncogene homolog 1 (5,21,22) AKT2 v-akt murine thymoma viral oncogene homolog 2 (4) ALB Albumin (4) ALK Anaplastic lymphoma receptor tyrosine kinase (22) AMPH Amphiphysin (24) ANK3 Ankyrin 3, node of Ranvier (ankyrin G) (4) ANKRD12 Ankyrin repeat domain 12 (4) ANO1 Anoctamin 1, calcium activated chloride channel (4) APC Adenomatous polyposis coli (4,5,21,22,25,28) APOB Apolipoprotein B [including Ag(x) antigen] (4) AR Androgen receptor (5,21-23) ARAP1 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1 (4) ARHGAP35 Rho GTPase activating protein 35 (21) ARID1A AT rich interactive domain 1A (SWI-like) (4,5,21,22,24,25,27,28) ARID1B AT rich interactive domain 1B (SWI1-like) (4,5,22) ARID2 AT rich interactive domain 2 (ARID, RFX-like) (4,5,22,24,25,27,28) ARID4A AT rich interactive domain 4A (RBP1-like) (28) ARID5B AT rich interactive domain 5B (MRF1-like) (21) ASPM Asp (abnormal
    [Show full text]
  • 0268D98d499c00a44e5d919f5d
    Hindawi Publishing Corporation Stem Cells International Volume 2016, Article ID 5184601, 18 pages http://dx.doi.org/10.1155/2016/5184601 Research Article Phenotypic and Functional Characterization of Mesenchymal Stem/Multipotent Stromal Cells from Decidua Basalis of Human Term Placenta F. M. Abomaray,1,2,3 M. A. Al Jumah,1 K. O. Alsaad,4 D. Jawdat,1 A. Al Khaldi,5 A. S. AlAskar,1 S. Al Harthy,6 A. M. Al Subayyil,1 T. Khatlani,1 A. O. Alawad,6 A. Alkushi,4,7 B. Kalionis,8 and M. H. Abumaree1,7 1 King Abdullah International Medical Research Center, Mail Code 1515, P.O. Box 22490, Riyadh 11426, Saudi Arabia 2Department of Clinical Science, Intervention and Technology, Division of Obstetrics and Gynecology, Karolinska Institutet, 14186 Stockholm, Sweden 3Center for Hematology and Regenerative Medicine, Karolinska Institutet, 14186 Stockholm, Sweden 4King Abdulaziz Medical City, Department of Pathology, P.O. Box 22490, Riyadh 11426, Saudi Arabia 5King Abdulaziz Medical City, Division of Cardiac Surgery, P.O. Box 22490, Riyadh, Saudi Arabia 6National Center for Stem Cell Technology, Life Sciences and Environment Research Institute, King Abdulaziz City for Science and Technology, P.O. Box 6086, Riyadh 11442, Saudi Arabia 7College of Science and Health Professions, King Saud bin Abdulaziz University for Health Sciences, Mail Code 3124, P.O. Box 3660, Riyadh 11481, Saudi Arabia 8Department of Obstetrics and Gynaecology, University of Melbourne and Department of Perinatal Medicine Pregnancy Research Centre, Royal Women’s Hospital, Parkville, VIC 3052, Australia Correspondence should be addressed to M. H. Abumaree; [email protected] Received 5 November 2015; Revised 14 December 2015; Accepted 5 January 2016 Academic Editor: Albert Rizvanov Copyright © 2016 F.
    [Show full text]
  • Anti-CD18 / LFA1 Beta Antibody (ARG41484)
    Product datasheet [email protected] ARG41484 Package: 100 μl anti-CD18 / LFA1 beta antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes CD18 / LFA1 beta Tested Reactivity Hu, Ms, Rat Tested Application ICC/IF, IHC-P, WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name CD18 / LFA1 beta Antigen Species Human Immunogen Recombinant protein of Human CD18 / LFA1 beta. Conjugation Un-conjugated Alternate Names MF17; LAD; CD antigen CD18; MFI7; MAC-1; Cell surface adhesion glycoproteins LFA-1/CR3/p150,95 subunit beta; LCAMB; Integrin beta-2; Complement receptor C3 subunit beta; LFA-1; CD18 Application Instructions Application table Application Dilution ICC/IF 1:50 - 1:200 IHC-P 1:50 - 1:200 WB 1:500 - 1:2000 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Positive Control Mouse thymus Calculated Mw 85 kDa Observed Size ~ 98 kDa Properties Form Liquid Purification Affinity purified. Buffer PBS (pH 7.3), 0.02% Sodium azide and 50% Glycerol. Preservative 0.02% Sodium azide Stabilizer 50% Glycerol Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw www.arigobio.com 1/3 cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. Note For laboratory research only, not for drug, diagnostic or other use. Bioinformation Gene Symbol ITGB2 Gene Full Name integrin, beta 2 (complement component 3 receptor 3 and 4 subunit) Background This gene encodes an integrin beta chain, which combines with multiple different alpha chains to form different integrin heterodimers.
    [Show full text]
  • Knock-Out Validated Antibodies from Cloud-Clone Cat.No
    Knock-out validated antibodies from Cloud-Clone Cat.No. Target PAA778Hu01 B-Cell Leukemia/Lymphoma 2 (Bcl2) PAL763Hu01 Myxovirus Resistance 1 (MX1) PAB698Hu01 Lactate Dehydrogenase B (LDHB) PAA009Hu01 Angiopoietin 2 (ANGPT2) PAA849Ra01 Glycogen Phosphorylase, Liver (PYGL) PAA153Hu01 Alpha-Fetoprotein (aFP) PAF460Hu01 Folate Receptor 1, Adult (FOLR1) PAB233Hu01 Cyclin Dependent Kinase 4 (CDK4) PAA150Hu04 Carcinoembryonic Antigen (CEA) PAB905Hu01 Interleukin 7 Receptor (IL7R) PAC823Hu01 Thymidine Kinase 1, Soluble (TK1) PAH838Hu01 Isocitrate Dehydrogenase 2, mitochondrial (IDH2) PAK078Mu01 Fas Associating Death Domain Containing Protein (FADD) PAA537Hu01 Enolase, Neuron Specific (NSE) PAA651Hu01 Hyaluronan Binding Protein 1 (HABP1) PAB215Hu02 Fibrinogen Beta (FGb) PAB769Hu01 S100 Calcium Binding Protein A6 (S100A6) PAB231Hu01 Keratin 18 (KRT18) PAH839Hu01 Isocitrate Dehydrogenase 1, Soluble (IDH1) PAE748Hu01 Karyopherin Alpha 2 (KPNa2) PAB081Hu02 Heat Shock 70kDa Protein 1A (HSPA1A) PAA778Mu01 B-Cell Leukemia/Lymphoma 2 (Bcl2) PAA853Hu03 Caspase 8 (CASP8) PAA399Mu01 High Mobility Group Protein 1 (HMG1) PAA303Mu01 Galectin 3 (GAL3) PAA537Mu02 Enolase, Neuron Specific (NSE) PAA994Ra01 Acid Phosphatase 1 (ACP1) PAB083Ra01 Superoxide Dismutase 2, Mitochondrial (SOD2) PAB449Mu01 Enolase, Non Neuronal (NNE) PAA376Mu01 Actinin Alpha 2 (ACTN2) PAA553Ra01 Matrix Metalloproteinase 9 (MMP9) PAA929Bo01 Retinol Binding Protein 4, Plasma (RBP4) PAA491Ra02 Keratin 2 (KRT2) PAC025Hu01 Keratin 8 (KRT8) PAB231Mu01 Keratin 18 (KRT18) PAC598Hu03 Vanin 1 (VNN1)
    [Show full text]
  • New Mesh Headings for 2018 Single Column After Cutover
    New MeSH Headings for 2018 Listed in alphabetical order with Heading, Scope Note, Annotation (AN), and Tree Locations 2-Hydroxypropyl-beta-cyclodextrin Derivative of beta-cyclodextrin that is used as an excipient for steroid drugs and as a lipid chelator. Tree locations: beta-Cyclodextrins D04.345.103.333.500 D09.301.915.400.375.333.500 D09.698.365.855.400.375.333.500 AAA Domain An approximately 250 amino acid domain common to AAA ATPases and AAA Proteins. It consists of a highly conserved N-terminal P-Loop ATPase subdomain with an alpha-beta-alpha conformation, and a less-conserved C- terminal subdomain with an all alpha conformation. The N-terminal subdomain includes Walker A and Walker B motifs which function in ATP binding and hydrolysis. Tree locations: Amino Acid Motifs G02.111.570.820.709.275.500.913 AAA Proteins A large, highly conserved and functionally diverse superfamily of NTPases and nucleotide-binding proteins that are characterized by a conserved 200 to 250 amino acid nucleotide-binding and catalytic domain, the AAA+ module. They assemble into hexameric ring complexes that function in the energy-dependent remodeling of macromolecules. Members include ATPASES ASSOCIATED WITH DIVERSE CELLULAR ACTIVITIES. Tree locations: Acid Anhydride Hydrolases D08.811.277.040.013 Carrier Proteins D12.776.157.025 Abuse-Deterrent Formulations Drug formulations or delivery systems intended to discourage the abuse of CONTROLLED SUBSTANCES. These may include physical barriers to prevent chewing or crushing the drug; chemical barriers that prevent extraction of psychoactive ingredients; agonist-antagonist combinations to reduce euphoria associated with abuse; aversion, where controlled substances are combined with others that will produce an unpleasant effect if the patient manipulates the dosage form or exceeds the recommended dose; delivery systems that are resistant to abuse such as implants; or combinations of these methods.
    [Show full text]
  • Integrin and Gene Network Analysis Reveals That ITGA5 and ITGB1 Are Prognostic in Non-Small-Cell Lung Cancer
    Journal name: OncoTargets and Therapy Article Designation: Original Research Year: 2016 Volume: 9 OncoTargets and Therapy Dovepress Running head verso: Zheng et al Running head recto: ITGA5 and ITGB1 are prognostic in NSCLC open access to scientific and medical research DOI: http://dx.doi.org/10.2147/OTT.S91796 Open Access Full Text Article ORIGINAL RESEARCH Integrin and gene network analysis reveals that ITGA5 and ITGB1 are prognostic in non-small-cell lung cancer Weiqi Zheng Background: Integrin expression has been identified as a prognostic factor in non-small-cell Caihui Jiang lung cancer (NSCLC). This study was aimed at determining the predictive ability of integrins Ruifeng Li and associated genes identified within the molecular network. Patients and methods: A total of 959 patients with NSCLC from The Cancer Genome Atlas Department of Radiation Oncology, Guangqian Hospital, Quanzhou, Fujian, cohorts were enrolled in this study. The expression profile of integrins and related genes were People’s Republic of China obtained from The Cancer Genome Atlas RNAseq database. Clinicopathological characteristics, including age, sex, smoking history, stage, histological subtype, neoadjuvant therapy, radiation therapy, and overall survival (OS), were collected. Cox proportional hazards regression models as well as Kaplan–Meier curves were used to assess the relative factors. Results: In the univariate Cox regression model, ITGA1, ITGA5, ITGA6, ITGB1, ITGB4, and ITGA11 were predictive of NSCLC prognosis. After adjusting for clinical factors, ITGA5 (odds ratio =1.17, 95% confidence interval: 1.05–1.31) andITGB1 (odds ratio =1.31, 95% confidence interval: 1.10–1.55) remained statistically significant. In the gene cluster network analysis, PLAUR, ILK, SPP1, PXN, and CD9, all associated with ITGA5 and ITGB1, were identified as independent predictive factors of OS in NSCLC.
    [Show full text]
  • Integrin Αdβ2 (Cd11d/CD18) Modulates Leukocyte Accumulation, Pathogen Clearance, and Pyroptosis in Experimental Salmonella Typhimurium Infection
    ORIGINAL RESEARCH published: 24 May 2018 doi: 10.3389/fimmu.2018.01128 Integrin αDβ2 (CD11d/CD18) Modulates Leukocyte Accumulation, Pathogen Clearance, and Pyroptosis in Experimental Salmonella Typhimurium Infection Danielle de Oliveira Nascimento 1, Adriana Vieira-de-Abreu 1,2, Angélica F. Arcanjo 1, Patricia Torres Bozza 1, Guy A. Zimmerman 2* and Hugo Caire Castro-Faria-Neto 1* 1Laboratório de Immunofarmacologia, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil, 2Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, United States Edited by: β2 integrins are critical in host defense responses to invading pathogens and inflam- Celio Geraldo Freire-de-Lima, Universidade Federal do Rio de mation. Previously, we reported that genetic deficiency of integrin αDβ2 in mice altered Janeiro, Brazil outcomes in experimental systemic infections including accelerated mortality in animals Reviewed by: infected with Salmonella enterica serovar Typhimurium. Here, we show that deficiency of Juliana Dutra Barbosa Da Rocha, αDβ2 results in impaired accumulation of leukocytes in response to peritoneal infection University of Toronto, Canada Eden Ramalho Ferreira, by S. Typhimurium, impaired pathogen clearance in vivo, defective bacterial elimination Federal University of São Paulo, Brazil by cultured peritoneal macrophages, and enhanced pyroptosis, a cell death process Laura Noelia Cariddi, α β National University of Río Cuarto, triggered by Salmonella. Salmonella-infected animals deficient in D 2 had increased Argentina levels of peritoneal cytokines in addition to other markers of pyroptosis, which may *Correspondence: contribute to inflammatory injury and increased mortality in the context of impaired Guy A. Zimmerman bacterial killing. These observations indicate important contributions of leukocyte integrins [email protected]; Hugo Caire Castro-Faria-Neto to the host response in experimental Salmonella infection and reveal previous activities of [email protected] αDβ2 in bacterial infection.
    [Show full text]
  • Petri Nykvist Integrins As Cellular Receptors for Fibril-Forming And
    Copyright © , by University of Jyväskylä ABSTRACT Nykvist, Petri Integrins as cellular receptors for fibril-forming and transmembrane collagens Jyväskylä: University of Jyväskylä, 2004, 127 p. (Jyväskylä Studies in Biological and Environmental Science, ISSN 1456-9701; 137) ISBN 951-39-1773-8 Yhteenveto: Integriinit reseptoreina fibrillaarisille ja transmembraanisille kollageeneille Diss. The two integrin-type collagen receptors α1β1 and α2β1 integrins are structurally very similar. However, cells can concomitantly express both receptors and it has been shown that these collagen receptor integrins have distinct signaling functions, and their binding to collagen may lead to opposite cellular responses. In this study, fibrillar collagen types, I, II, III, and V, and network like structure forming collagen type IV tested were recognized by both integrins at least at the αI domain level. The αI domain recognition does not always lead for cell spreading behavior. In addition transmembrane collagen type XIII was studied. CHO-α1β1 cells could spread on recombinant human collagen type XIII, unlike CHO-α2β1 cells. This finding was supported by αI domain binding studies. The results indicate, that α1β1 and α2β1 integrins do have different ligand binding specificities and distinct collagen recognition mechanisms. A common structural feature in the collagen binding αI domains is the presence of an extra helix, named helix αC. A αC helix deletion reduced affinity for collagen type I when compared to wild-type α2I domain, which indicated the importance of helix αC in collagen type I binding. Further, point mutations in amino acids Asp219, Asp259, Asp292 and Glu299 resulted in weakened affinity for collagen type I. Cells expressing double mutated α2Asp219/Asp292 integrin subunit showed remarkably slower spreading on collagen type I, while spreading on collagen type IV was not affected.
    [Show full text]
  • High Integrin Α3 Expression Is Associated with Poor Prognosis in Patients with Non-Small Cell Lung Cancer
    1378 Original Article High integrin α3 expression is associated with poor prognosis in patients with non-small cell lung cancer Qianping Li1#*, Weijie Ma1#, Shuai Chen2, Eddie C. Tian1, Sixi Wei1**, Reggie R. Fan1, Tao Wang3, Chihong Zhou3, Tianhong Li1,4^ 1Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis School of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, California, USA; 2Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, California, USA; 3Department of Pathology and Laboratory Medicine, University of California Davis School of Medicine, Sacramento, CA, USA; 4Department of Internal Medicine, Veterans Affairs Northern California Health Care System, Mather, California, USA Contributions: (I) Conception and design: Q Li, W Ma, T Li; (II) Administrative support: T Li; (III) Provision of study materials or patients: T Li; (IV) Collection and assembly of data: Q Li, W Ma, EC Tian, RR Fan, T Wang, C Zhou; (V) Data analysis and interpretation: Q Li, W Ma, S Chen, T Li; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. #These authors contributed equally to this work. Correspondence to: Tianhong Li, MD, PhD. Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis School of Medicine, University of California Davis Comprehensive Cancer Center, 4501 X Street, Suite 3016, Sacramento, California 95817, USA. Email: [email protected]. Background: We previously showed that α3β1 integrin is a novel cancer biomarker and drug target in non- small cell lung cancer (NSCLC). This study characterized the integrin α3 (ITGA3) expression on patient specimens. Methods: Tissue microarrays (TMAs) were prepared from archival tissue blocks containing 161 patients, which included 91 adenocarcinoma (LUAD), 46 squamous carcinomas (LUSC), and 24 other histology types.
    [Show full text]
  • Prdc Cdna Insert Product Line
    hIntegrin αD/CD11d VersaClone cDNA Catalog Number: RDC0876 Specifications: Description This shuttle vector contains the complete ORF for the gene of interest, Gene: hITGAD along with a Kozak consensus sequence for optimal translation initiation. It is inserted NotI to AscI. The gene insert is flanked with Accession: NP_005344 convenient multiple cloning sites which can be used to easily cut and transfer the gene cassette into your desired expression vector. Insert size: 3499bp Preparation and Storage Concentration: 10µg at 0.2μg/μL Formulation cDNA is provided in 10 mM Tris-Cl, pH 8.5 Shipping Ships at ambient temperature Stability 1 year from date of receipt when stored at -20°C to -80°C Storage Use a manual defrost freezer and avoid repeated hIntegrin αD/CD11d freeze-thaw cycles. cDNA Plasmid NdeI ITGAD integrin, alpha D BbeI NarI SfoI [ Homo sapiens (human) ] HpaI EcoRV Also known as: ADB2; CD11D SspI NotI XmnI EagI Summary: Bsu36I Integrins are heterodimeric NmeAIII BsaI BsaBI integral cell-surface proteins AhdI AMP known to participate in cell AccIII adhesion as well as cell-surface KflI mediated signaling. ITGAD, the BsaAI PmlI integrin alpha D subunit, associates with beta 2. Integrin RDC0876 COLE1 alphaD/beta2 is a receptor for 6233 bps ICAM3 and VCAM1. It is SexAI expressed in myelomonocytic Van91I BtgZI cells and leukocytes. ITGAD may hITGAD (1-1161) AvrII Eco47III SapI play a role in the atherosclerotic XhoI PspXI process such as clearing EcoRI lipoproteins from plaques and in ApoI SalI AgeI phagocytosis of blood-borne XbaI BsrGI Bst1107I pathogens, particulate matter, BssHII AscI BsmI AarI and senescent erythrocytes from ClaI BclI the blood.
    [Show full text]